Should You Buy Cardinal Health, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Cardinal Health, Inc. (CAH) scores a robust 7.9/10 on our 32-signal Quality of Company framework. At the current market price of $232.65 and a $54.1B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 6 of 10 CirclFi valuation models project upside for Cardinal Health, Inc. (CAH) at $232.65 — the model consensus leans bullish, with a Quality Score of 7.9/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Cardinal Health, Inc. (CAH) in 2026?
What Is the Bull Case vs the Bear Case for Cardinal Health, Inc. (CAH)?
| Bull case — $517.63 target (+122.5%) | Bear case — $59.51 target (-74.4%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Cardinal Health, Inc.'s rating of 7.9/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $59.51 (-74.4%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, 6 of 10 models identify upside from $232.65 to a median fair value of $271.18, indicating the market hasn't fully priced in Cardinal Health, Inc.'s earnings power. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +196.9% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $517.63 (+122.5%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously. | |
| Scale advantage: as a $54.1B large-cap company, Cardinal Health, Inc. benefits from economies of scale, institutional investor demand, and index inclusion that smaller competitors lack. |
How Does CAH Compare to Its Medical Distribution Peers?
Valuation data pages: COR · HSIC · MCK · YI · AHG · FOCL · SNYR · HKPD
Which Other Stocks Score Like CAH on Quality?
Closest companies to CAH’s Quality of Company score of 7.9/10, across all industries.
- NRP — Natural Resource Partners L.P. (QOC 7.9) · analysis
- EBMT — Eagle Bancorp Montana, Inc. (QOC 7.9) · analysis
- AUB — Atlantic Union Bankshares Corporation (QOC 7.9) · analysis
- EE — Excelerate Energy, Inc. (QOC 7.9) · analysis
- HPQ — HP Inc. (QOC 7.9) · analysis
- AEO — American Eagle Outfitters, Inc. (QOC 7.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Cardinal Health, Inc. (CAH) Worth Buying in 2026?
Cardinal Health, Inc. leans positive in our analysis — 6/10 models bullish, median fair value of $271.18 vs. $232.65, QOC 7.9/10. The case is constructive but not overwhelming, and the 4 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. Cardinal Health, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CAH Stock?
Should I buy CAH stock right now?
Based on CirclFi's multi-model analysis, 6 of 10 models see upside for CAH at $232.65. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.9/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Cardinal Health, Inc.?
Key risks include: wide model disagreement (770% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Distribution companies. Always diversify and consult a financial advisor.
How does CAH compare to its competitors?
Among Medical Distribution peers, CAH holds a Quality Score of 7.9/10. Comparable companies include COR (QOC 8.3), HSIC (QOC 7.3), MCK (QOC 8.7). The relative ranking helps investors identify whether CAH offers better fundamental quality than alternatives in the same sector.
Is CAH a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CAH's Quality Score of 7.9/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy CAH at?
CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $59.51 to $517.63. At $232.65, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CAH.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad